We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-12.93%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$102B
AUM Growth
-$16.3B
Cap. Flow
+$749M
Cap. Flow %
0.73%
Top 10 Hldgs %
23.72%
Holding
4,322
New
210
Increased
1,790
Reduced
1,850
Closed
304
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
APLE icon
1951
Apple Hospitality REIT
APLE
$3.71B
$2.09M ﹤0.01%
142,734
+43,284
+44% +$716K
BRKR icon
1952
Bruker
BRKR
$9.03B
$2.09M ﹤0.01%
33,347
-2,032
-6% -$125K
GPI icon
1953
Group 1 Automotive
GPI
$3.17B
$2.09M ﹤0.01%
12,289
+1,024
+9% +$178K
SCM icon
1954
Stellus Capital Investment Corp
SCM
$249M
$2.09M ﹤0.01%
187,487
-16,529
-8% -$213K
EFAD icon
1955
ProShares MSCI EAFE Dividend Growers ETF
EFAD
$64.1M
$2.09M ﹤0.01%
60,316
+504
+0.8% +$18.6K
VIOG icon
1956
Vanguard S&P Small-Cap 600 Growth ETF
VIOG
$1.13B
$2.08M ﹤0.01%
22,958
-262
-1% -$25.6K
BOX icon
1957
Box
BOX
$4.48B
$2.08M ﹤0.01%
82,580
-32,990
-29% -$922K
FNDB icon
1958
Schwab Fundamental US Broad Market Index ETF
FNDB
$1.48B
$2.08M ﹤0.01%
123,957
+93,090
+302% +$1.69M
RMT
1959
Royce Micro-Cap Trust
RMT
$772M
$2.08M ﹤0.01%
248,262
-93,333
-27% -$872K
ELS icon
1960
Equity Lifestyle Properties
ELS
$12.4B
$2.07M ﹤0.01%
29,422
+3,438
+13% +$257K
TEVA icon
1961
Teva Pharmaceuticals
TEVA
$42.6B
$2.06M ﹤0.01%
274,150
-26,854
-9% -$234K
PBA icon
1962
Pembina Pipeline
PBA
$28.4B
$2.06M ﹤0.01%
58,159
-101
-0.2% -$3.89K
AOD
1963
abrdn Total Dynamic Dividend Fund
AOD
$1.13B
$2.05M ﹤0.01%
254,083
+10,044
+4% +$87.4K
IEP icon
1964
Icahn Enterprises
IEP
$5.33B
$2.05M ﹤0.01%
42,658
+1,239
+3% +$64.3K
TW icon
1965
Tradeweb Markets
TW
$21.9B
$2.05M ﹤0.01%
29,971
-359
-1% -$26.1K
HYI
1966
Western Asset High Yield Opportunity Fund Inc
HYI
$135M
$2.04M ﹤0.01%
167,914
-3,842
-2% -$49.5K
LZB icon
1967
La-Z-Boy
LZB
$1.64B
$2.04M ﹤0.01%
86,162
+9,441
+12% +$243K
VSH icon
1968
Vishay Intertechnology
VSH
$5.11B
$2.04M ﹤0.01%
114,436
+446
+0.4% +$8.47K
BPOP icon
1969
Popular Inc
BPOP
$11.2B
$2.04M ﹤0.01%
+26,462
New +$2.11M
ESRT icon
1970
Empire State Realty Trust
ESRT
$817M
$2.04M ﹤0.01%
289,512
+13,444
+5% +$109K
SAR icon
1971
Saratoga Investment
SAR
$312M
$2.03M ﹤0.01%
84,808
+3,122
+4% +$80.9K
ETG
1972
Eaton Vance Tax-Advantaged Global Dividend Income Fund
ETG
$1.87B
$2.03M ﹤0.01%
126,024
+14,042
+13% +$248K
SSTK icon
1973
Shutterstock
SSTK
$208M
$2.03M ﹤0.01%
35,416
+9,812
+38% +$657K
CRSP icon
1974
CRISPR Therapeutics
CRSP
$5.22B
$2.02M ﹤0.01%
33,255
-18,335
-36% -$1.08M
EVH icon
1975
Evolent Health
EVH
$471M
$2.02M ﹤0.01%
65,741
-736
-1% -$21.4K

Similar funds

Raymond James & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Raymond James & Associates held 4,322 positions worth $102B, down 14% from $119B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q2 2022 filing shows 210 new, 1,790 increased, 1,850 reduced and 304 closed positions. Its largest new stake was Aspen Technology Inc: 54,037 shares worth $9.93M. The largest sale was iShares Core MSCI EAFE ETF, an estimated $551M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q2 2022 buy was Aspen Technology Inc: 54,037 shares worth $9.93M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q2 2022, an estimated $471M increase.
  • Raymond James & Associates's biggest Q2 2022 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $551M.
  • Raymond James & Associates fully exited ASPEN TECHNOLOGY INC in Q2 2022, selling an estimated $21.5M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $102B portfolio in Q2 2022.
  • Raymond James & Associates opened 210 new positions and closed 304 in Q2 2022.
  • Raymond James & Associates's portfolio value fell 14% quarter-over-quarter to $102B.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.